Trials / Completed
CompletedNCT00002136
A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Daiichi Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
Detailed description
Patients receive intravenous DS-4152 by infusion once every 21 days; courses may repeat. Patients undergo weekly follow-up. A punch biopsy will be obtained from patients with Kaposi's sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tecogalan sodium |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002136. Inclusion in this directory is not an endorsement.